{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:03:31Z","timestamp":1784628211595,"version":"3.55.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although prognostic significance of 1q21 chromosomal abnormalities (CAs) in multiple myeloma (MM) has been validated, the real world data (RWD) of its practical utilization in the clinical practice remain to be of interest. The aim of study was to analyze the prognostic significance of 1q21 CAs in the RWD settings of the routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included 328 newly diagnosed MM patients (NDMM, pts), diagnosed during the period 2018-2024. The distribution according to the second Revision of the International Staging System (R2-ISS) was 25.6%, 22.9%, 46.3% and 5.2% with scores 1, 2, 3 and 4, respectively. The 1q21 CAs, gain1q21 and amp1q21, were detected in 33.7% pts (gain1q21 in 12.4% pts, and amp1q21 in 21.3% pts). Patients were treated predominantly (238pts, 72.6%) with Bortezomib (Bz) plus immunomodulatory drugs (IMids) based triplets. Autologous stem cell transplantation (ASCT) were performed in 87\/114 potential transplant candidates (76.3%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall response rate (ORR \u2265PR) was achieved in 86.3% of the patients, regardless of the findings of gain 1q21 (p=0.113) or amp1q21 (p=0.757) in comparison to the patients without 1q21 CAs. Patients without 1q21 CAs had significantly longer progression-free survival in comparison to the patients with gain 1q21 or amp1q21 (PFS, p=0.000). The overall survival of the patients with amp1q21 was significantly shorter in comparison to the patients with gain1q21 or those without 1q21 CAs (OS, p=0.043).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Presence of the 1q21 CAs retains clear impact on the course of disease in MM patients outside of clinical trials. As a part of validated prognostic indices, finding of 1q21 CAs represents valuable prognostic biomarker, which may contribute in bringing up treatment choice, especially in the circumstances of limited accessibility to the new treatment modalities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1765235","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:39:33Z","timestamp":1770791973000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiple myeloma in the real world settings: prognostic significance of 1q21 chromosomal abnormalities - single center experience"],"prefix":"10.3389","volume":"16","author":[{"given":"Aleksandra","family":"Sretenovic","sequence":"first","affiliation":[{"name":"Clinic of Hematology, University Clinical Center of Serbia","place":["Belgrade, Serbia"]},{"name":"Medical Faculty, University of Belgrade","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Mitrovic","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Center of Serbia","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Bukumiric","sequence":"additional","affiliation":[{"name":"Medical Faculty, University of Belgrade","place":["Belgrade, Serbia"]},{"name":"Institute of Statistics and Bioinformatics, Medical Faculty, University of Belgrade","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Vukosavljevic","sequence":"additional","affiliation":[{"name":"University Clinical Hospital Center \u201cZvezdara\u201d, Department for Hemato-Oncology","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalija","family":"Kecman","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Center of Serbia","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelica","family":"Jovanovic","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Center of Serbia","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija Dencic","family":"Fekete","sequence":"additional","affiliation":[{"name":"Medical Faculty, University of Belgrade","place":["Belgrade, Serbia"]},{"name":"Institute of Pathology, Medical Faculty, University of Belgrade","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enisa","family":"Zaric","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Clinical Center of Podgorica, Medical Faculty, University of Podgorica","place":["Podgorica, Montenegro"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Bila","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Center of Serbia","place":["Belgrade, Serbia"]},{"name":"Medical Faculty, University of Belgrade","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02196-0","article-title":"Genomic landscape of multiple myeloma and its precursor conditions","volume":"57","author":"Alberge","year":"2025","journal-title":"Nat Genet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3390\/cells10061360","article-title":"Role of 1q21 in multiple myeloma: from pathogenesis to possible therapeutic targets","volume":"10","author":"Burroughs Garc\u00eda","year":"2021","journal-title":"Cells"},{"key":"B5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/10245330512331390140","article-title":"Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma","volume":"10","author":"Shaughnessy","year":"2005","journal-title":"Hematology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-06164-2","article-title":"The prognostic impact of 1q21 gain\/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China","volume":"104","author":"Li","year":"2025","journal-title":"Ann Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34641","article-title":"The prognostic role of 1q21 gain\/amplification in newly diagnosed multiple myeloma: The faster, the worse","volume":"129","author":"Wang","year":"2023","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with clinical features, response, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: IMWG recommendations","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN evidence-based guidelines for diagnosis, treatment and follow-up of MM","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System (R-ISS) for multiple myeloma","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000478935","article-title":"The revised international staging system compared to the classical international staging system better discriminates risk groups among transplant-ineligible multiple myeloma patients","volume":"40","author":"Bila","year":"2017","journal-title":"Oncol Res Treat"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02614.","article-title":"Second revision of ISS (R2-ISS)","volume":"40","author":"D\u2019Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"IMWG consensus criteria for response and MRD assessment","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.3324\/haematol.2009.016436","article-title":"Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation","volume":"95","author":"Neben","year":"2010","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.3324\/haematol.2015.136929","article-title":"Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma","volume":"101","author":"Weinhold","year":"2016","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.26639","article-title":"Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications","volume":"97","author":"Kastritis","year":"2022","journal-title":"Am J Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"961421","DOI":"10.3389\/fonc.2022.961421","article-title":"Multiple myeloma with amplification of chromosome 1q: therapeutic opportunities and challenges","volume":"12","author":"Sklavenitis-Pistofidis","year":"2022","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41408-023-00943-2","article-title":"Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma","volume":"13","author":"Ozga","year":"2023","journal-title":"Blood Cance J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.mayocp.2017.01.003","article-title":"Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy","volume":"92","author":"Dingli","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e70216","DOI":"10.1002\/hem3.70216","article-title":"European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma","volume":"9","author":"Bolli","year":"2025","journal-title":"Hemasphere"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"613045","DOI":"10.1155\/2015\/613045","article-title":"Multiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapy","volume":"2015","author":"Zeng","year":"2015","journal-title":"Stem Cells Int"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2023","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma (IMROZ)","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00273-5","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplant-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02482-6","article-title":"International Myeloma Working Group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e70260","DOI":"10.1002\/hem3.70260","article-title":"Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network","volume":"9","author":"Van de Donk","year":"2025","journal-title":"HemaSphere"}],"updated-by":[{"DOI":"10.3389\/fonc.2026.1920779","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1765235\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:41:19Z","timestamp":1784626879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1765235\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":43,"alternative-id":["10.3389\/fonc.2026.1765235"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1765235","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"article-number":"1765235"}}